Tomasz Brzozowski, Peter C Konturek, Anthony P Moran, Robert Pajdo, Slawomir Kwiecien, Stanislaw J Konturek, Zbigniew Sliwowski, Danuta Drozdowicz, Wieslaw W Pawlik, Eckhart G Hahn
Index: J. Pharmacol. Exp. Ther. 310(1) , 116-25, (2004)
Full Text: HTML
Lipopolysaccharide (LPS) is one of the virulence factors in the Helicobacter pylori (Hp)-infected stomach, but it remains unknown whether single and prolonged pretreatment with Hp-LPS can affect the course of gastric damage induced by aspirin (ASA). We compared the effects of Hp-LPS with those induced by LPSs isolated from intestinal Bacteroides fragilis, Yersinia enterocolitica, and Campylobacter jejuni applied for 4 days on acute ASA-induced gastric lesions in rats. The area of ASA-induced gastric lesions, gastric blood flow (GBF), expression of mRNA and protein of leptin and plasma leptin, gastrin, interleukin-1beta, and tumor necrosis factor-alpha levels were examined. Single (once) or repeated (five times) i.p. injections of Hp-LPS (1 mg/kg) or intestinal LPSs failed to produce macroscopic gastric damage and did not affect the GBF when compared with vehicle. Hp-LPS injected repeatedly suppressed the gastric acid secretion, up-regulated leptin mRNA and protein, and increased plasma leptin and gastrin levels. Hp-LPS significantly reduced the ASA-induced gastric damage and the accompanying decline in the GBF, and these effects were significantly attenuated by capsaicin denervation and selective antagonism of cholecystokinin-B (CCK2) receptors by RPR-102681 [N-(metoxy-3 phenyl) N-(N-methyl N-phenyl-carbamylmethyl) carbamoylmethyl]-3 ureido]-3 phenyl]-2 propronique] but not by loxiglumide, an antagonist of CCK1 receptors. We conclude that 1) daily application of Hp-LPS enhances gastric mucosal resistance against ASA damage due to the increase of GBF and the expression and release of leptin and gastrin exerting trophic and gastroprotective effects, and 2) this enhanced resistance to ASA damage in Hp-LPS-adapted stomach is mediated by the sensory afferents and specific CCK2/gastrin receptors.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Loxiglumide
CAS:107097-80-3 |
C21H30Cl2N2O5 |
Effect of cholecystokinin-A receptor blockade on postprandia...
2002-10-01 [Neurogastroenterol. Motil. 14(5) , 519-25, (2002)] |
Stimulatory effect of N-methyltyramine, a congener of beer, ...
2010-02-01 [Alcohol. Clin. Exp. Res. 34 Suppl 1 , S14-7, (2010)] |
Inhibitory effect of loxiglumide (CR 1505), a cholecystokini...
2002-03-01 [World J. Surg. 26(3) , 359-65, (2002)] |
Effects of the cholecystokinin A receptor antagonist loxiglu...
2006-03-01 [Pancreas 32(2) , 190-6, (2006)] |
Sensitive SPE-HPLC method to determine a novel angiotensin-A...
2004-04-16 [J. Pharm. Biomed. Anal. 35(2) , 321-9, (2004)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved